AZD6738 Plus Durvalumab in Biliary Tract Cancer

Status Recruiting

Clinical Trial Summary

This trial will enroll advanced biliary tract cancer patients who have been previously treated with immunotherapy in either the 2nd or 3rd line. Patients will be treated with AZD6738 and Durvalumab combination.

Clinical Trial Description

This is a single arm, phase II study. Advanced BTC patients who have been previously treated with immunotherapy in either the 2nd or 3rd line will be enrolled. Patients will be treated with AZD6738 and Durvalumab combination. One cycle consists of 4weeks. Response evaluation will be done every 8 weeks (every 2 cycles) of treatment 1. Tumor biopsy is mandatory: screening, after 8weeks (1st-response evaluation), at disease progression (PD) 2. blood sampling for biomarker study is mandatory: every cycles 3. To evaluate the metabolic changes by AZD6738 and Durvalumab combination : 18 F-FDG PET is mandatory : screening, after 8 weeks (1st-response evaluation) ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04298008
Study type	Interventional
Source	Seoul National University Hospital
Contact
Status	Recruiting
Phase	Phase 2
Start date	June 25, 2020
Completion date	December 31, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06376604` - Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies	N/A
Completed	`NCT03753542` - Effect of Nurse-led Education on Parent's Anxiety and Depression on Managing Side Effects of Chemotherapy	N/A
Not yet recruiting	`NCT05022628` - Clinical Study of Radiotherapy Combined With Donafenib for Neoadjuvant Treatment of Patients With HCC With Portal Vein Carcinoma Thrombosis	Phase 4
Completed	`NCT04207359` - Effects of Creatine Supplementation in Breast Cancer Survivors	N/A
Active, not recruiting	`NCT04489173` - TAS102 in Patients With ER-positive, HER2-negative Advanced Breast Cancer	Phase 2
Completed	`NCT04173195` - Comfort Talk (CT) During Outpatient Chemotherapy	N/A
Recruiting	`NCT06041477` - Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC	Phase 3
Recruiting	`NCT05014399` - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Recruiting	`NCT03275194` - HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy	Phase 2
Recruiting	`NCT04808466` - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Recruiting	`NCT06421610` - OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.	Phase 1
Completed	`NCT05131490` - Effect on Adaptation to Cancer of Mobile Application Developed for Gynecological Cancer Patients	N/A
Completed	`NCT04118322` - The Effect of Peppermint Oil on Nausea, Vomiting and Retching in Cancer Patients Undergoing Chemotherapy	N/A
Recruiting	`NCT06043999` - Salvage Chemotherapy Versus Total Mesorectal Resection for Local Resection Rectal Cancer Patients	N/A
Recruiting	`NCT05515796` - Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors	Phase 2
Not yet recruiting	`NCT04845490` - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy	Phase 2
Recruiting	`NCT04989985` - S-1 and Oxaliplatin (SOX) Plus Sintilimab in the Locally Advanced Esophagogastric Junction Adenocarcinoma	Phase 2
Recruiting	`NCT05424692` - Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy of Colorectal Cancer	N/A
Recruiting	`NCT05992337` - New Biomarkers in the Prediction of Chemotherapy-induced Cardiotoxicity.
Enrolling by invitation	`NCT04027478` - Can Fasting Decrease the Side Effects of Chemotherapy?	N/A